Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Wolfram Eisenreich

Zeren Wang

Thomas Friedl

Nantharat Pearnchob

Sreeraj Macha

Peter Schneider

Danping Li

Albert Josef Barta

Florian Sommer

Karl Gerhard Wagner

Albert Barta

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Clower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.

Extended release tablet formulations of flibanserin and method for manufacturing the same

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Growing community of inventors

Ulm, Germany

Wolfram Eisenreich